TY - JOUR
T1 - Update on the management of inflammatory breast cancer
AU - Cristofanilli, Massimo
AU - Buzdar, Aman U.
AU - Hortobágyi, Gabriel N.
PY - 2003
Y1 - 2003
N2 - Inflammatory breast cancer (IBC) is the most aggressive manifestation of primary breast carcinoma, with the clinical and biological characteristics of a rapidly proliferating disease. The multidisciplinary management of IBC has changed in the past 3 decades and is presently clearly outlined in sequence, with preoperative or neoadjuvant chemotherapy representing the mainstay of treatment. Anthracyclines and taxanes are the most effective cytotoxic agents in the management of primary breast cancer and should be the standard of treatment for women with IBC. Locoregional treatment includes radiotherapy with or without surgery and continues to play a major role after appropriate medical treatment. The rnany investigations into the particular molecular determinants of IBC development have provided several interesting new therapeutic targets. Combination regimens that include angiogenic modulators, farnesyl transferase inhibitors, and p53 modulators hold great promise in the medical management of IBC. Future therapeutic approaches should focus on these discoveries so that we can improve the overall prognosis for women with IBC.
AB - Inflammatory breast cancer (IBC) is the most aggressive manifestation of primary breast carcinoma, with the clinical and biological characteristics of a rapidly proliferating disease. The multidisciplinary management of IBC has changed in the past 3 decades and is presently clearly outlined in sequence, with preoperative or neoadjuvant chemotherapy representing the mainstay of treatment. Anthracyclines and taxanes are the most effective cytotoxic agents in the management of primary breast cancer and should be the standard of treatment for women with IBC. Locoregional treatment includes radiotherapy with or without surgery and continues to play a major role after appropriate medical treatment. The rnany investigations into the particular molecular determinants of IBC development have provided several interesting new therapeutic targets. Combination regimens that include angiogenic modulators, farnesyl transferase inhibitors, and p53 modulators hold great promise in the medical management of IBC. Future therapeutic approaches should focus on these discoveries so that we can improve the overall prognosis for women with IBC.
KW - Inflammatory breast cancer
KW - Targeted therapies
UR - http://www.scopus.com/inward/record.url?scp=0037255004&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037255004&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.8-2-141
DO - 10.1634/theoncologist.8-2-141
M3 - Review article
C2 - 12697939
AN - SCOPUS:0037255004
SN - 1083-7159
VL - 8
SP - 141
EP - 148
JO - Oncologist
JF - Oncologist
IS - 2
ER -